4
Changes in Ownership
Bicara Therapeutics Inc. Filed Acc 0001628280-26-015778
Chief Executive Officer sold 8,234 shares at an average $18.74 ($154,325)
- Chief Executive Officer acquired 8,234 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Mazumdar Claire Chief Executive Officer | 2026-03-04 | Option exercise 10b5-1 | +2,631 | $3.79 | $9,971 | 342,023 | D |
| Mazumdar Claire Chief Executive Officer | 2026-03-04 | Sale 10b5-1 | −2,631 | $18.73 | $49,289 | 339,392 | D |
| Mazumdar Claire Chief Executive Officer | 2026-03-05 | Option exercise 10b5-1 | +1,786 | $3.79 | $6,769 | 341,178 | D |
| Mazumdar Claire Chief Executive Officer | 2026-03-05 | Sale 10b5-1 | −1,786 | $18.74 | $33,464 | 339,392 | D |
| Mazumdar Claire Chief Executive Officer | 2026-03-06 | Option exercise 10b5-1 | +3,817 | $3.79 | $14,466 | 343,209 | D |
| Mazumdar Claire Chief Executive Officer | 2026-03-06 | Sale 10b5-1 | −3,817 | $18.75 | $71,572 | 339,392 | D |
| Derivatives | |||||||
| Mazumdar Claire Chief Executive Officer | 2026-03-04 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,631 | 233,476 | D | ||
| Mazumdar Claire Chief Executive Officer | 2026-03-05 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,786 | 231,690 | D | ||
| Mazumdar Claire Chief Executive Officer | 2026-03-06 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,817 | 227,873 | D | ||
| Open-market sales · 8,234 sh · avg $18.74 · $154,325 | |||||||
Loading xslF345X05/wk-form4_1772843254.xml…